The structure of a new pancreatic lipase inhibitor, lipstatin, produced by Streptomyces toxytridni was determined as (25, 35, 55,7Z, 1 0Z )-5-[(5' )-2-formamido-4-methylpentanoyloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic lactone by spectroscopic and chemical methods.
Streptomyces toxytridni (NRRL15443) was found to produce a specific inhibitor of pancreatic lipase which we have named lipstatin1}. Lipstatin was found mainly in the mycelium and was extracted, after recovery of the biomass by centrifugation, with methanol. The organic extract was concentrated, the residue suspended in water and then extracted with hexane-ethyl acetate. This extract was chromatographed on silica gel. Further purification was done by preparative reverse phase chromatography on a Lobar Lichroprep RP-8 column, yielding pure lipstatin as a pale yellow oil0.
Elemental analysis indicated the following composition : Table 1 ) supported the molecular formula C29H49NO5.The IR spectrum of lipstatin shows a characteristic peak at 1823 cm"1. This indicates the presence of a^-lactone moiety in the compound. In 1978 Umezawa et alP described an esterase inhibitor of microbial origin, esterastin, containing a /3-lactone moiety. A comparison of the *H NMRspectra of esterastin reported by Umezawaet alP and of lipstatin (see Table  2 ) revealed some structural similarity of these two compounds. It was obvious, that the main difference is due to different amino acid side chains. Catalytic hydrogenation of lipstatin (1) gave a crystalline tetrahydrolipstatin (2). Chemical ionization mass spectra (CI-MS) (NH3) m/z 51 3 (M +NH4)+ , 496 (M + H)+. Treatment of 1 with K2CO3in methanol at 50°C gave the unsaturated <5-lactone 3 (MS m/z 332 (M)) and iV-formyl-L-leucine methyl ester (4), which was identical with a reference sample prepared from L-leucine methyl ester. Alkaline hydrolysis of 1 at room temperature followed by catalytic i?-toluenesulfonic acid treatment afforded the <Hactone 5, a degradation product of esterastin, found by Umezawa et alP OH NMR, Table 2 ). Mild hydrolysis of 1 with NaHCO3in MeOHgave two methyl esters 6 and 7. 6 could be identified as the <5-hydroxymycolic acid methyl esterf described by Umezawa et alP OH NMR, Table 2 ).
Mycolic acid is the generic name of higher fatty acids possessing a-alkyl and /3-hydroxy groups. The IR spectrum of 7 was similar to that of lipstatin (1), only the characteristic peak at 1823 cm"1 (/3-lactone) was missing. In the XHNMRthe signals of the iV-formyl-L-leucine side chain (Table 2) were present. In the MS peaks at mjz 505 (M-H2O) and 492 (M-OCH3) were observed.
Acetylation of 7 with acetic anhydride in pyridine gave a mono-O-acetyl derivative (CI-MS (NH3) m/z 583 (M+NH4)+, 566 (M+H)+).
Fromthese observations the structure of 7 can be proposed to be the d-hydroxymycolic acid methyl ester (6) esterified with iV-formyl-L-leucine. Tetrahydrolipstatin (2) was decarboxylated at 200°C followed by saponification to give the (6> henicos-7ii-en-10-ol (8) found by Umezawa et alP. Periodate-permanganate oxidation of 8 gave (S)-3-hydroxymyristic acid (9), enanthic acid (10) also described by Umezawaet alP and lauric acid (ll).
Fromthe fact that hydrolysis of esterastin and lipstatin afforded the identical d-hydroxymycolic acid methyl ester (6) and <5-lactone 5, it can be concluded that both inhibitors have the same <5-hydroxymycolic acid /Mactone moiety. This was further confirmed by the degradation products 8, 9 and 10. The hydrolysis products 4 and 7 indicate that in lipstatin <5-hydroxymycolic acid /3-lactone is esterified with iV-formyl-L-leucine. From the foregoing results, the structure of lipstatin can be proposed to be (2S, 3S, 5S, 7Z, 1 0Z)-5-[(5)-2-formamido-4-methylpentanoyloxy]-2-hexyl-3-hydroxy-7, 1 0-hexadecadi-enoic lactone. The structure of tetrahydrolipstatin (2) was recently confirmed by Barbier and Schneider by total synthesis3).
Experimental
Melting points were determined on a Tottoli capillary melting point apparatus and are uncorrected. IR spectra were determined on a Nicolet 7199 fourier transformation (FT)-IR instrument. NMR spectra were recorded in CDC13on Bruker HX270 and WM400 spectrometers; chemical shifts in ppmdownfield from internal TMSand coupling constants in Hz are given. The mass spectra were obtained on a MM707F-DS 2050 mass spectrometer (Vacuum Generators, Altrincham, England), using direct introduction, vaporizing the samples from the tip of a glass rod close to the electron beam. Ionizing energy was 70 eV, ion-source temperature was 250°C. Lipstatin (1) Lipstatin was isolated as described previouslyx).
[ayg _19°(c i9 CHC13); UV *££= nm (s) 270 (sh, 34); electron impact mass spectra (EI-MS) m/z Tetrahydrolipstatin (2) 138 mg 1 were stirred for 3 hours in 10 ml ethanol with 60 mg 5%Pd-C under a hydrogen atmos- 
Unsaturated d-Lactone 3 and iV-Formyl-L-leucine
Methyl Ester (4) 97 mg 1 dissolved in 10 ml MeOHwere stirred with 30 mg K2CO3for 1 hour at 50°C. The solvent was removed in vacuo, the residue was dissolved in CHC13and washed with water. After evaporation of the solvent the residue was separated on a silica gel column with CHC13-EtOAc(1 : 1) and CHC13 to afford ll mg iV-formyl-L-leucine methyl ester (4) and 27 mg of the unsaturated <5-lactone 3. 
d-Lactone 5
172 mg 1 were dissolved in 0.7 ml 1 m KOHand 35 ml dioxane and stirred at room temp. After 120 minutes, 0.085 ml 1 m KOHand 15 ml dioxane were added and the reaction continued for 105 minutes. Then the solution was neutralized with 1 n HC1and coned in vacuo. The residue was taken up in diethyl ether, washed with satd NaCl soln and dried over Na2SO4. The ether was evaporated, the residue was dissolved in 50 ml CH2C12, a few mg of p-toluenesulfonic acid were added and the mixture was stirred for 90 minutes at room temp. The CH2C12layer was evaporated and the residue was taken up in diethyl ether. The solution was washed with NaHCO3 solution, satd NaCl soln, dried over Na2SO4and coned in vacuo. The crude product was separated by column chromatography on silica gel with hexane-EtOAc (5 : 1) and (2: 1) to give 51 mg <5-lactone 5, 31 mg unsaturated 8-lactone 3 and 25 mg starting material.
<5 Methyl Esters 6 and 7 110 mg 1 were dissolved in ll ml MeOH,19 mg NaHCO3added and the mixture stirred for 20 hours at roomtemp. Then the reaction mixture was filtered, the filtrate coned under reduced pressure and the residue chromatographed on silica gel. Hexane -EtOAc (1 : 1) eluted 13 mg 6 as an (6' )-Henicos-7£' -en-1 0-ol (8) 243 mg tetrahydrolipstatin (2) were heated for 40 minutes at 200°C in vacuo. The reaction product was hydrolyzed in 15 ml 0.1 m NaOH (22 hours at room temp). The solution was diluted with water and extracted with diethyl ether. The extract was washed with satd NaCl soln and dried over Na2SO4. The ether was evaporated in vacuo and the residue chromatographed on a silica gel column with hexane-EtOAc (19 : 1) to give 113 mg henicos-7£'-en-10-ol (8) as white solid: MP 41~42°C (literature25 : MP 40.5~41°C); IR QKJB^cm-1 3337, 3250, 1065, 958; gas chromatography (GQ-EI-MS of the TMS-derivative C24H50SiO, m\z 382 (M), 367 (M-CH3), 257 (M-C9H17); TO NMR d 0.9 (6H, br t, 1-H3 and 21-H3), 1.09-1.59 (16H, br), 1.61 (s, 10-OH), 1.81~2.41 (6H, m, 6-H2, 9-H2 and ll-H2), 3.57 (10-H, m), 5. 35 and 5.58 (2H, m, /=16 Hz, .
Periodate-permanganate Oxidation of (5)-Henicos-7£'-en-10-ol (8) 60 mg 8 dissolved in 45 ml tert-BuQH were added to a solution of624 mg NaIO4 and 12 mg KMnO4 in 130 ml of water adjusted to pH 8.5 with Na2CO3. The mixture was stirred for 15 hours at room temp and then filtered. The filtrate was adjusted to pH 2 and extracted with CHC13. The organic layer was washed with satd NaCl soln and the solvent was evaporated in vacuo. The residue was purified by TLC on silica gel with CHC13 -MeOH(19 : 1). 15 mg (S)-3-hydroxymyristic acid (9) and 20 mg of an oil, containing enanthic acid (10) and lauric acid (ll) were obtained. 0S)-3-Hydroxymyristic Acid 9: MP 71~72°C; M2D3 +12.5°(c 0.8, CHC13) (literature25 : MP 72.5-73°C, M2D7 +13°(c 1, CHC13)); GC-EI-MS of the TMS-methylester derivative C18H38SiO3, m/z 330
